These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7262644)

  • 1. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.
    Maguire ED; Pay GF; Turney J; Wallis RB; Weston MJ; White AM; Williams LC; Woods HF
    Haemostasis; 1981; 10(3):153-64. PubMed ID: 7262644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
    Pay GF; Wallis RB; Zelaschi D
    Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the relationship between ex vivo and in vivo effects of sulphinpyrazone in the guinea pig.
    Butler KD; Wallis RB; White AM
    Haemostasis; 1979; 8(3-5):353-60. PubMed ID: 159853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulphinpyrazone (Anturan) in man.
    Maguire ED; Pay GF; Wallis RB; White AM
    Thromb Res; 1981 Feb; 21(3):321-7. PubMed ID: 7245142
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.
    Nunn B; James FJ
    Br J Clin Pharmacol; 1980 Mar; 9(3):239-45. PubMed ID: 7362733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway.
    Pay GF; Wallis RB; Zelaschi D
    Biochem Soc Trans; 1980 Dec; 8(6):727-8. PubMed ID: 7461266
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig.
    Chignard M; Wal F; Lefort J; Vargaftig BB
    Eur J Pharmacol; 1982 Feb; 78(1):71-9. PubMed ID: 6804248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulphinpyrazone metabolism during long-term therapy.
    Pedersen AK; Jakobsen P
    Br J Clin Pharmacol; 1981 Jun; 11(6):597-603. PubMed ID: 7272176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic therapy for vascular prosthesis: an experimental model testing platelet inhibitory drugs.
    McCollum CN; Crow MJ; Rajah SM; Kester RC
    Surgery; 1980 Jun; 87(6):668-76. PubMed ID: 6445604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.
    Del Maschio A; Livio M; Cerletti C; De Gaetano G
    Eur J Pharmacol; 1984 Jun; 101(3-4):209-14. PubMed ID: 6432556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part I: Single dose study.
    Ritschel WA; Kuo BS
    Biopharm Drug Dispos; 1987; 8(1):1-9. PubMed ID: 3107626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulphinpyrazone and indomethacin for inhibition of platelet prostaglandin synthesis.
    Huijgens PC; van den Berg CA; Imandt LM; Langenhuijsen MM
    Thromb Res; 1981 Nov; 24(3):267-70. PubMed ID: 7336383
    [No Abstract]   [Full Text] [Related]  

  • 13. Controlled ex-vivo effect of sulfinpyrazone on platelet function of myocardial infarction patients.
    Cortellaro M; Fassio G; Boschetti C; Basagni M; Polli EE
    Haematologica; 1979 Apr; 64(2):173-89. PubMed ID: 112008
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of sulphinpyrazone and dipyridamole on capillary bleeding time in man.
    Weston MJ; Rubin MH; Langley PG; Westaby S; Williams R
    Thromb Res; 1977 Jun; 10(6):833-40. PubMed ID: 882967
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.
    Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
    Br J Clin Pharmacol; 1982 Feb; 13(2):177-85. PubMed ID: 7059415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin and other platelet-aggregation inhibiting drugs.
    Gallus AS
    Med J Aust; 1985 Jan; 142(1):41-7. PubMed ID: 3880861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part II: Multiple dose study.
    Kuo BS; Ritschel WA
    Biopharm Drug Dispos; 1987; 8(1):11-21. PubMed ID: 3580509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sulfinpyrazone and its metabolite G25671 on platelet activation and desensitization and on bronchoconstriction induced by the prostaglandin endoperoxide analog U46619.
    Hatmi M; del Maschio A; Lefort J; de gaetano G; Vargaftig BB; Cerletti C
    J Pharmacol Exp Ther; 1987 May; 241(2):623-7. PubMed ID: 3106620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphinpyrazone inhibits platelet function and enhances blood fibrinolytic activity in the rat.
    Hussaini IM; Moore PK
    Thromb Res; 1988 Nov; 52(4):337-41. PubMed ID: 3201405
    [No Abstract]   [Full Text] [Related]  

  • 20. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.
    Di Minno G; Cerbone AM; Mattioli PL; Turco S; Iovine C; Mancini M
    J Clin Invest; 1985 Feb; 75(2):328-38. PubMed ID: 3156146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.